Parathyroid hormone measurement in CKD
The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (e.g., 150–300...
Gespeichert in:
| Veröffentlicht in: | Kidney international 2010-01, Vol.77 (2), p.93-100 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Kidney international |
| container_volume | 77 |
| creator | Souberbielle, Jean-Claude P. Roth, Hubert Fouque, Denis P. |
| description | The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (e.g., 150–300 pg/ml in patients with CKD stage 5). The quality of the PTH assay is of paramount importance, as it contributes to the therapeutic decision. Indeed, when the PTH concentration is above these target values, drugs that decrease PTH secretion, such as active vitamin D compounds or calcimimetic agents, may be given and the doses are then adapted according to the evolution of the PTH concentration. By contrast, if the PTH concentration is below the target range, any treatment that may decrease PTH secretion is stopped to avoid adynamic bone disease and associated extra-skeletal calcifications. The aim of this article is to discuss the main features and pitfalls related to PTH measurement in the setting of CKD. |
| doi_str_mv | 10.1038/ki.2009.374 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733347974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815542051</els_id><sourcerecordid>1930581641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-32c7b20ac7ee31951126000372af216ebc9160e1b20c611e666a55e270ad30ca3</originalsourceid><addsrcrecordid>eNp90M1LwzAYBvAgipsfJ-86BOdBOpO8TdMeZX7iQA96Dln6jmVb25m0wv57MzsmiHgKCT_eJ-9DyAmjA0YhvZ7bAac0G4CMd0iXCQ4Rk0Lski6lqYi4gLRDDryf0XDPgO6TDstSFt5ll_RftdP1dOUqm_emlSuqEnsFat84LLCse7bsDZ9vj8jeRC88Hm_OQ_J-f_c2fIxGLw9Pw5tRZOIU6gi4kWNOtZGIwDLBGE9CKkiuJ5wlODYZSyiyYEzCGCZJooVALqnOgRoNh-Synbt01UeDvlaF9QYXC11i1XglASCWmYyD7P8rOYPQREoDPP8FZ1XjyrBFMDQooGlAVy0yrvLe4UQtnS20WylG1bplNbdq3bKC7-zTzchmXGD-Yze1BnCxAdobvZg4XRrrt47zOBMyE8Gdta7UdSh8C-Z2ndVGiVZgaP3TolPeWCwN5tahqVVe2T-_-AUiZp0u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210135308</pqid></control><display><type>article</type><title>Parathyroid hormone measurement in CKD</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Souberbielle, Jean-Claude P. ; Roth, Hubert ; Fouque, Denis P.</creator><creatorcontrib>Souberbielle, Jean-Claude P. ; Roth, Hubert ; Fouque, Denis P.</creatorcontrib><description>The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (e.g., 150–300 pg/ml in patients with CKD stage 5). The quality of the PTH assay is of paramount importance, as it contributes to the therapeutic decision. Indeed, when the PTH concentration is above these target values, drugs that decrease PTH secretion, such as active vitamin D compounds or calcimimetic agents, may be given and the doses are then adapted according to the evolution of the PTH concentration. By contrast, if the PTH concentration is below the target range, any treatment that may decrease PTH secretion is stopped to avoid adynamic bone disease and associated extra-skeletal calcifications. The aim of this article is to discuss the main features and pitfalls related to PTH measurement in the setting of CKD.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1038/ki.2009.374</identifier><identifier>PMID: 19812537</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>Basingstoke: Elsevier Inc</publisher><subject>assay standardization ; Biological and medical sciences ; Blood Chemical Analysis - standards ; bone mineral metabolism ; chronic kidney disease ; Humans ; KDOQI ; Kidneys ; Medical sciences ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; parathyroid hormone ; Parathyroid Hormone - blood ; radioimmunoassay ; Renal failure ; Renal Insufficiency, Chronic - blood ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Kidney international, 2010-01, Vol.77 (2), p.93-100</ispartof><rights>2010 International Society of Nephrology</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jan 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-32c7b20ac7ee31951126000372af216ebc9160e1b20c611e666a55e270ad30ca3</citedby><cites>FETCH-LOGICAL-c483t-32c7b20ac7ee31951126000372af216ebc9160e1b20c611e666a55e270ad30ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/210135308?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22495795$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19812537$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Souberbielle, Jean-Claude P.</creatorcontrib><creatorcontrib>Roth, Hubert</creatorcontrib><creatorcontrib>Fouque, Denis P.</creatorcontrib><title>Parathyroid hormone measurement in CKD</title><title>Kidney international</title><addtitle>Kidney Int</addtitle><description>The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (e.g., 150–300 pg/ml in patients with CKD stage 5). The quality of the PTH assay is of paramount importance, as it contributes to the therapeutic decision. Indeed, when the PTH concentration is above these target values, drugs that decrease PTH secretion, such as active vitamin D compounds or calcimimetic agents, may be given and the doses are then adapted according to the evolution of the PTH concentration. By contrast, if the PTH concentration is below the target range, any treatment that may decrease PTH secretion is stopped to avoid adynamic bone disease and associated extra-skeletal calcifications. The aim of this article is to discuss the main features and pitfalls related to PTH measurement in the setting of CKD.</description><subject>assay standardization</subject><subject>Biological and medical sciences</subject><subject>Blood Chemical Analysis - standards</subject><subject>bone mineral metabolism</subject><subject>chronic kidney disease</subject><subject>Humans</subject><subject>KDOQI</subject><subject>Kidneys</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>radioimmunoassay</subject><subject>Renal failure</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90M1LwzAYBvAgipsfJ-86BOdBOpO8TdMeZX7iQA96Dln6jmVb25m0wv57MzsmiHgKCT_eJ-9DyAmjA0YhvZ7bAac0G4CMd0iXCQ4Rk0Lski6lqYi4gLRDDryf0XDPgO6TDstSFt5ll_RftdP1dOUqm_emlSuqEnsFat84LLCse7bsDZ9vj8jeRC88Hm_OQ_J-f_c2fIxGLw9Pw5tRZOIU6gi4kWNOtZGIwDLBGE9CKkiuJ5wlODYZSyiyYEzCGCZJooVALqnOgRoNh-Synbt01UeDvlaF9QYXC11i1XglASCWmYyD7P8rOYPQREoDPP8FZ1XjyrBFMDQooGlAVy0yrvLe4UQtnS20WylG1bplNbdq3bKC7-zTzchmXGD-Yze1BnCxAdobvZg4XRrrt47zOBMyE8Gdta7UdSh8C-Z2ndVGiVZgaP3TolPeWCwN5tahqVVe2T-_-AUiZp0u</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Souberbielle, Jean-Claude P.</creator><creator>Roth, Hubert</creator><creator>Fouque, Denis P.</creator><general>Elsevier Inc</general><general>Nature Publishing Group</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Parathyroid hormone measurement in CKD</title><author>Souberbielle, Jean-Claude P. ; Roth, Hubert ; Fouque, Denis P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-32c7b20ac7ee31951126000372af216ebc9160e1b20c611e666a55e270ad30ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>assay standardization</topic><topic>Biological and medical sciences</topic><topic>Blood Chemical Analysis - standards</topic><topic>bone mineral metabolism</topic><topic>chronic kidney disease</topic><topic>Humans</topic><topic>KDOQI</topic><topic>Kidneys</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>radioimmunoassay</topic><topic>Renal failure</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Souberbielle, Jean-Claude P.</creatorcontrib><creatorcontrib>Roth, Hubert</creatorcontrib><creatorcontrib>Fouque, Denis P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Souberbielle, Jean-Claude P.</au><au>Roth, Hubert</au><au>Fouque, Denis P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Parathyroid hormone measurement in CKD</atitle><jtitle>Kidney international</jtitle><addtitle>Kidney Int</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>77</volume><issue>2</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid hormone (PTH) concentration of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (e.g., 150–300 pg/ml in patients with CKD stage 5). The quality of the PTH assay is of paramount importance, as it contributes to the therapeutic decision. Indeed, when the PTH concentration is above these target values, drugs that decrease PTH secretion, such as active vitamin D compounds or calcimimetic agents, may be given and the doses are then adapted according to the evolution of the PTH concentration. By contrast, if the PTH concentration is below the target range, any treatment that may decrease PTH secretion is stopped to avoid adynamic bone disease and associated extra-skeletal calcifications. The aim of this article is to discuss the main features and pitfalls related to PTH measurement in the setting of CKD.</abstract><cop>Basingstoke</cop><pub>Elsevier Inc</pub><pmid>19812537</pmid><doi>10.1038/ki.2009.374</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0085-2538 |
| ispartof | Kidney international, 2010-01, Vol.77 (2), p.93-100 |
| issn | 0085-2538 1523-1755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733347974 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | assay standardization Biological and medical sciences Blood Chemical Analysis - standards bone mineral metabolism chronic kidney disease Humans KDOQI Kidneys Medical sciences Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure parathyroid hormone Parathyroid Hormone - blood radioimmunoassay Renal failure Renal Insufficiency, Chronic - blood Urinary system involvement in other diseases. Miscellaneous |
| title | Parathyroid hormone measurement in CKD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Parathyroid%20hormone%20measurement%20in%20CKD&rft.jtitle=Kidney%20international&rft.au=Souberbielle,%20Jean-Claude%20P.&rft.date=2010-01-01&rft.volume=77&rft.issue=2&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1038/ki.2009.374&rft_dat=%3Cproquest_cross%3E1930581641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210135308&rft_id=info:pmid/19812537&rft_els_id=S0085253815542051&rfr_iscdi=true |